INSULIN, ORAL ANTIDIABETIC DRUGS AND GLUCAGON MCQs Part – 2

TOP 10 MCQ

1. Sitagliptins act on which of the following target [GPAT-2014, 2024]
(a) PPAR
(b) Insulin receptor
(c) GLP
(d) DPP4

2. Normal value of HbA1c falls in the range of [GPAT-2023 SHIFT-II]
(a) 0.1% to 0.8%
(b) 6.5% to 7.5%
(c) 21.5% to 24.5%
(d) 51.5% to 53.5%

3. Exenatide is a [GPAT-2023 SHIFT-III]
(a) Glucagon like peptide 1 (GLP1) receptor agonist
(b) Diphenyl Peptidase-4 (DPP4) inhibitors
(c) Facilitator of glucose transport across the cell
(d) Inhibitor of glucose absorption in the GIT

4. Which among the following statement is CORRECT with respect to their mechanism of antidiabetic action [GPAT-2023 SHIFT-II]
(a) Dapagliflozin/Canagliflozin – Sodium glucose cotransporter-2 inhibitor
(b) Glipizide/Gliclazide – Dipeptidyl peptidase-4 inhibitors
(c) Linagliptin/Alogliptin – AMPK activators
(d) Acarbose / Voglibose – K+ATP channel blockers

5. Match List I with List II Match the following with their mechanism of action [GPAT-2022]

LIST I                                                                                          LIST II
Mechanism of action                                                             Drugs
DPP4 inhibitors                                                                         [P] Metformin
KATP Channel blocker                                                             [Q] Pioglitazone
PPARγ activator                                                                        [R] Glimepiride
AMP Activator                                                                           [S] Teneligliptin
                                                                                                     [T] α glucosidase inhibitor
Choose the correct answer from the options given below
(a) 1 – [Q], 2 – [T], 3 – [R], 4 – [S]
(b) 1 – [Q], 2 – [R], 3 – [S], 4 – [P]
(c) 1 – [S], 2 – [R], 3 – [Q], 4 – [P]
(d) 1 – [S], 2 – [P], 3 – [T], 4 – [R]

6. Which of the following clinical feature is not responsible for insulin resistance in type 2 diabetes [GPAT-2022]

(a) Increased LDL

(b) Increased HDL

(c) Reduced HDL

(d) Increased triglycerides

7. Which among the following statement is CORRECT with respect to their mechanism of action [GPAT-2021]

(a) Sitagliptin/Vildagliptin: Dipeptidyl peptidase-4 inhibitors

(b) Dapagliflozin/Canagliflozine: AMPK activators

(c) Glibenclamide/ Glimepiride: α-Glucosidase inhibitors

(d) Acarose/Metformin: KATP channel blockers

8. The oral oligosaccharide hypoglycemic agent, which is administered at the start of the meal is [GPAT-2018]

(a) Pioglitazone

(b) Miglitol

(c) Acarbose

(d) Glimepiride

9. LISPRO an analog of insulin defers from insulin by which amino acids [GPAT-2016]

(a) Lysine and proline

(b) Leucine

(c) Lysine and phenylalanine

(d) Leucine and phenylalanine

10. Which antidiabetics work through amplification of the incretin pathway [GPAT-2016]
(a) DPP-4 Inhibitor
(b) Glucagon like peptide-1
(c) Sodium glucose co-transporter-2 inhibitor
(d) Thiazolidinedione

ANSWER KEY